Accuplex Launch New ELISA for Detection of Invasive Aspergillosis
Accuplex are launching its latest addition to the SideroTec range of tests, SideroTec-Asp. The SideroTec-Asp is an ELISA based test that enables direct detection of the fungus Aspergillus fumigatus responsible for Invasive Aspergillosis (IA), an infection which can prove fatal to patients with other underlying conditions including those with cancer, organ transplant patients and any person with who may be immunocompromised. During the recent Covid pandemic Invasive Aspergillosis caused mortality in over 30% of patients in the ICU. And recent data indicates the condition is significantly underdiagnosed, that many patients suffering from COPD are seriously affected by Invasive Aspergillosis (COPD and IA). The World Health Organization has recently added detection of Aspergillus fumigatus to their Essential Diagnostics list ( WHO EDL ).
The test was developed by Professor Sean Doyle and his team in Maynooth University. The SideroTec-Asp ELISA enables direct detection of a Triacetylyfusarinine C, a biomarker of infection in urine samples, allowing non-invasive testing. Accuplex are also adapting the test into a lateral flow test for direct application with urine samples, offering the potential for home use in any patient prone to IA.
The SideroTec-Asp ELISA, currently available for Research Use Only, uses a unique monoclonal antibody generated by Professor Doyle and his team. The Monoclonal antibody is also available for research application.
For more information contact info@accuplexdiagnostics.com
